The addition of tucatinib to ado-trastuzumab emtansine (T-DM1) significantly improved progression-free survival vs placebo plus T-DM1 in patients with previously treated HER2-positive metastatic breast cancer, including those with brain metastases.
Treatment with the all-oral triplet of tucatinib, letrozole, and palbociclib yielded clinically meaningful efficacy results and had an acceptable safety profile in patients with hormone receptor–positive, HER2-positive metastatic breast cancer.
KENILWORTH (NJ) (dpa-AFX) - Seagen Inc. (SGEN) said Thursday that the U.S. Food and Drug Administration has granted accelerated approval to Tukysa (tucatinib) in combination with trastuzumab for
-Phase 2 trial showed chemotherapy-free TUKYSA combination resulted in clinically meaningful and durable tumor responses- -Results presented in late-breaking oral session at the ESMO World Congress
- Data Accepted for Presentation at ESMO World Congress on Gastrointestinal Cancer - Seagen Inc. (Nasdaq:SGEN) today announced positive topline results from the pivotal phase 2 MOUNTAINEER clinical